{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:10:34Z","timestamp":1767831034914,"version":"3.49.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Tafenoquine is a novel 8-aminoquinoline antimalarial drug recently approved by the U.S. Food and Drug Administration (FDA) for the radical cure of acute<jats:named-content content-type=\"genus-species\">Plasmodium vivax<\/jats:named-content>malaria, which is the first new treatment in almost 60 years.<\/jats:p>","DOI":"10.1128\/aac.00711-18","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T11:26:40Z","timestamp":1536578800000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-5796","authenticated-orcid":false,"given":"Nilay","family":"Thakkar","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline Research and Development, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin A.","family":"Green","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Global Health Group, Stockley Park, Uxbridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-1566","authenticated-orcid":false,"given":"Gavin C. K. W.","family":"Koh","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Global Health Group, Stockley Park, Uxbridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9649-4847","authenticated-orcid":false,"given":"Stephan","family":"Duparc","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tenero","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline Research and Development, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navin","family":"Goyal","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline Research and Development, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.30875\/4348b814-en"},{"key":"e_1_3_3_3_2","volume-title":"Guidelines for the treatment of malaria","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Guidelines for the treatment of malaria. 2015. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00718-15"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002299"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-418"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62568-4"},{"key":"e_1_3_3_8_2","volume-title":"Guidance for industry: population pharmacokinetics","author":"U.S. Food and Drug Administration","year":"1999","unstructured":"U.S. Food and Drug Administration. 1999. Guidance for industry: population pharmacokinetics. U.S. Food and Drug Administration, Silver Spring, MD."},{"key":"e_1_3_3_9_2","first-page":"S11","article-title":"Tafenoquine (TQ; SB252263) population pharmacokinetic model and effect dose simulation in Plasmodium vivax malaria subjects","volume":"42","author":"Tenero D","year":"2015","unstructured":"Tenero D, Green J, Goyal N. 2015. Tafenoquine (TQ; SB252263) population pharmacokinetic model and effect dose simulation in Plasmodium vivax malaria subjects. J Pharmacokinet Pharmacodyn 42:S11\u2013S12.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01183-06"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01482.x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01068419"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1998.tb06190.x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0668-x"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12160"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1391212"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.302"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01748-15"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.04.018"},{"key":"e_1_3_3_20_2","volume-title":"Guideline on reporting the results of population pharmacokinetic analyses","author":"European Medicines Agency","year":"2007","unstructured":"European Medicines Agency. 2007. Guideline on reporting the results of population pharmacokinetic analyses. European Medicines Agency, London, United Kingdom."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_3_3_22_2","first-page":"S84","article-title":"Simulation from ODE-based population PK\/PD and systems pharmacology models in R with mrgsolve","volume":"42","author":"Baron KT","year":"2015","unstructured":"Baron KT, Gastonguay MR. 2015. Simulation from ODE-based population PK\/PD and systems pharmacology models in R with mrgsolve. J Pharmacokinet Pharmacodyn 42:S84\u2013S85.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-75969-2"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-98141-3","volume-title":"ggplot2 elegant graph data analysis","author":"Wickham H","year":"2009","unstructured":"Wickham H. 2009. ggplot2. ggplot2 elegant graph data analysis. Springer, New York, NY."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00711-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00711-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:20:21Z","timestamp":1693873221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00711-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1128\/AAC.00711-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.00711-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2018-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00711-18"}}